Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.

Blog Article

IntroductionThe Residual Cancer Burden (RCB) quantifies residual AEG BPE642020M Mastery A+ Rated Built In Electric Single Oven wh disease after neoadjuvant chemotherapy (NAC).Its predictive value has not been validated on large cohorts with long-term follow up.The objective of this work is to independently evaluate the prognostic value of the RCB index depending on BC subtypes (Luminal, HER2-positive and triple negative (TNBCs)).MethodsWe retrospectively evaluated the RCB index on surgical specimens from a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012.

We analyzed the association between RCB index and relapse-free survival (RFS), overall survival (OS) among the global population, after stratification by BC subtypes.Results717 patients were included (luminal BC (n = 222, 31%), TNBC (n = 319, 44.5%), HER2-positive (n = 176, 24.5%)).

After a median follow-up of 99.9 months, RCB index was significantly associated with RFS.The RCB-0 patients displayed similar prognosis when compared to HatsHat AccessoriesHat Band Calf Hair the RCB-I group, while patients from the RCB-II and RCB-III classes were at increased risk of relapse (RCB-II versus RCB-0: HR = 3.25 CI [2.

1-5.1] pConclusionRCB index is a reliable prognostic score.RCB accurately identifies patients at a high risk of recurrence (RCB-III) with TNBC or HER2-positive BC who must be offered second-line adjuvant therapies.